Analyst Viewpoint
Advantages of multiplex assays over singleplex assays and surge in prevalence of autoimmune diseases are driving the multiplex assays market value. The high cost of multiplex assay systems is a major barrier to their adoption.
Rise in usage of multiplexed point-of-care testing is likely to offer lucrative opportunities to vendors in the market.
Major manufacturers are offering custom assay development services that help end-users develop new analytes and multiplex new analytes with existing analytes. They are also developing products that provide a higher level of precision and automation to immunoassay workflow.
Assays are used in the life sciences sector in both research and clinical settings. Multiplex assays are immunoassays that employ magnetic beads to simultaneously measure a range of analytes in a single reaction.
These assays are considered to be derivatives of Enzyme-linked Immunosorbent Assay (ELISA). They are preferred over singleplex ELISA owing to their advantages such as high throughput, greater output per sample volume, and increased efficiency.
Traditional ELISA assays detect and measure a single analyte per plate whereas multiplex assays allow for the simultaneous detection of multiple analytes in a single well or reaction. Multiplex immunoassays improve workflows and save sample volume and time.
| Attribute | Detail |
|---|---|
| Drivers |
|
Multiplex immunoassays offer higher efficiency at a reduced expense compared to singleplex assays. They provide greater output per sample volume ratios and higher throughput indicating more resolute. Multiplexed assays are widely employed in detailed diagnostics and facilitate the R&D of personalized medicine.
Multiplex immunoassays conserve limited sample volume and lower cost per data point. They improve accuracy due to less sample handling and optimize productivity.
Multiplex immunoassays also save time and resources. They enable researchers to acquire more data from their samples. These advantages are boosting the multiplex assays market size.
Multiplex immunoassays are employed in the diagnosis, monitoring, and treatment of diseases. These immunoassays are considered to be beneficial for the simultaneous detection of different autoantibodies related to autoimmune diseases such as Crohn's disease, Rheumatoid Arthritis (RA), type 1 diabetes, and Multiple Sclerosis (MS).
According to the World Health Organization, over 1.8 million people have MS worldwide. Thus, rise in prevalence of autoimmune diseases is expected to spur the multiplex assays market growth in the near future.
Multiplex assay technology often requires specialized equipment and a validated antibody pair. Higher initial investment than singleplex devices also limits their usage. It is challenging and time-consuming to identify antibodies with high specificity using multiplex assays.
The use of multiplex assays can mean an exponential increase in the number of parameters. This requires assays to be carefully matched to function in the same buffer and the same analytical range without losing selectivity, precision, or accuracy. These challenges may limit the adoption of multiplex assay technology in the near future.
Multiplexed point-of-care testing (xPOCT) is a more complex form of POCT. It facilitates simultaneous on-site detection of different analytes from a single specimen. xPOCT is gaining traction in resource-limited settings in developing countries.
Multiplex Assay manufacturers are focused on the development of xPOCT systems that are a smart combination of high-performing devices with a low system complexity. These systems can offer on-site tests in a short time, even when used by non-experts, and ensure comparable results with clinical and central laboratory findings.
Multiplex assay companies are developing optimal multiplex assays that ensure specific and sensitive identification of multiple analytes in a single well reaction. They are employing hybrid workflows to reinvent the process of developing and designing multiplex assays.
Various studies are investing in the R&D of novel multiplex real-time polymerase chain reaction (qPCR) methods to simultaneously detect and differentiate zoonotic abortifacient agents in cattle, goats, and sheep. The development of such rapid, cost-saving, and reliable diagnostic tools can aid in the effective detection of various zoonotic diseases.
| Attribute | Detail |
|---|---|
| Leading Region | North America |
North America accounted for major multiplex assays market share in 2022. Presence of leading market players and rise in investment in R&D activities are fueling the market statistics in the region.
Vendors in North America are developing multiplex assays for infectious diseases. In 2022, the Food and Drug Administration (FDA) granted clearance to Alinity m STI Assay to simultaneously detect and differentiate 4 commonly sexually transmitted infections (STIs).
Surge in prevalence of STIs is driving the multiplex assays market dynamics of North America. According to the 2021 Centers for Disease Control and Prevention (CDC) analyses, 20% of the U.S. population-approximately one in five people - had an STI on any given day in 2018. Moreover, the infection cost the U.S. healthcare system nearly US$ 16 Bn in direct medical costs.
Key players operating in the multiplex assays market landscape are offering advanced bead-based immunoassays for the simultaneous detection of multiple analytes in a single well or reaction. They are developing products that provide consistent, high-quality results. These products help save time, labor, and cost.
DiaSorin S.p.A., Thermo Fisher Scientific, Inc., Seegene, Inc., Meso Scale Diagnostics, LLC, Abcam Limited, Bio-Rad Laboratories, Inc., QIAGEN, Merck KGaA, Quansys Biosciences, and Illumina, Inc. are key players operating in the multiplex assays industry.
These companies have been profiled in the multiplex assays market report based on various parameters including company overview, business segments, product portfolio, recent developments, business strategies, and financial overview.
| Attribute | Detail |
|---|---|
| Market Size in 2022 | US$ 3.2 Bn |
| Market Forecast (Value) in 2031 | US$ 5.9 Bn |
| Growth Rate (CAGR) | 6.9% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2021 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Market Segmentation |
|
| Regions Covered |
|
| Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 3.2 Bn in 2022
It is projected to advance at a CAGR of 6.9% during the forecast period
Advantages of multiplex assays over singleplex assays and surge in prevalence of autoimmune diseases
North America was the leading region in 2022
DiaSorin S.p.A., Thermo Fisher Scientific, Inc., Seegene, Inc., Meso Scale Diagnostics, LLC, Abcam Limited, Bio-Rad Laboratories, Inc., QIAGEN, Merck KGaA, Quansys Biosciences, and Illumina, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Multiplex Assays Market
4. Market Overview
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Multiplex Assays Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Product/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Multiplex Assays Market Analysis and Forecast, by Product
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product, 2017–2031
6.3.1. Instruments
6.3.2. Consumables
6.3.2.1. Reagents & Kits
6.3.2.2. Micropipettes & Microplates
6.3.2.3. Others
6.3.3. Software
6.4. Market Attractiveness, by Product
7. Global Multiplex Assays Market Analysis and Forecast, by Technology
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Technology, 2017–2031
7.3.1. Multiplex RT-PCR
7.3.2. Flow Cytometry
7.3.3. Luminescence
7.3.4. Fluorescence
7.3.5. Others
7.3.6. Market Attractiveness, by Technology
8. Global Multiplex Assays Market Analysis and Forecast, By Type
8.1. Introduction and Definitions
8.2. Key Findings/Developments
8.3. Market Value Forecast, By Type, 2017–2031
8.3.1. Protein
8.3.1.1. Planar
8.3.1.2. Bead-based
8.3.2. Nucleic Acid
8.3.2.1. Planar
8.3.2.2. Bead-based
8.3.3. Cell
8.4. Market Attractiveness, By Type
9. Global Multiplex Assays Market Analysis and Forecast, by Application
9.1. Introduction and Definitions
9.2. Key Findings/Developments
9.3. Market Value Forecast, by Application, 2017–2031
9.3.1. Research & Development
9.3.1.1. Drug Discovery & Research
9.3.1.2. Biomarker Research & Application
9.3.2. Diagnosis
9.3.2.1. Infectious Diseases
9.3.2.2. Autoimmune Diseases
9.3.2.3. Cancer
9.3.2.4. Cardiovascular Diseases
9.3.2.5. Neuroendocrine Diseases
9.3.2.6. Others
9.3.3. Others
9.4. Market Attractiveness, by Application
10. Global Multiplex Assays Market Analysis and Forecast, by End-user
10.1. Introduction and Definitions
10.2. Key Findings/Developments
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Biotechnology & Biopharmaceutical Companies
10.3.2. Academic & Research Centers
10.3.3. Diagnostic Centers
10.3.4. Hospitals
10.3.5. Others
10.4. Market Attractiveness, by End-user
11. Global Multiplex Assays Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region, 2017–2031
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness, by Region
12. North America Multiplex Assays Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product, 2017–2031
12.2.1. Instruments & Software
12.2.2. Kits & Reagents
12.2.3. Services
12.3. Market Attractiveness, by Product
12.4. Market Value Forecast, by Technology, 2017–2031
12.4.1. Conventional PCR
12.4.2. Singleplex PCR
12.4.3. Multiplex PCR
12.4.4. Real-time PCR
12.4.5. Others
12.5. Market Attractiveness, by Technology
12.6. Market Value Forecast, By Type, 2017–2031
12.6.1. Protein
12.6.1.1. Planar
12.6.1.2. Bead-based
12.6.2. Nucleic Acid
12.6.2.1. Planar
12.6.2.2. Bead-based
12.6.3. Cell
12.7. Market Attractiveness, By Type
12.8. Market Value Forecast, by Application, 2017–2031
12.8.1. Companion Animal
12.8.2. Livestock Animal
12.9. Market Attractiveness, by Application
12.10. Market Value Forecast, by End-user, 2017–2031
12.10.1. Biotechnology & Biopharmaceutical Companies
12.10.2. Academic & Research Centers
12.10.3. Diagnostic Centers
12.10.4. Hospitals
12.10.5. Others
12.11. Market Attractiveness, by End-user
12.12. Market Value Forecast, by Country/Sub-region, 2017–2031
12.12.1. U.S.
12.12.2. Canada
12.13. Market Attractiveness Analysis
12.13.1. By Product
12.13.2. By Technology
12.13.3. By Type
12.13.4. By Application
12.13.5. By End-user
12.13.6. By Country
13. Europe Multiplex Assays Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product, 2017–2031
13.2.1. Instruments
13.2.2. Consumables
13.2.2.1. Reagents & Kits
13.2.2.2. Micropipettes & Microplates
13.2.2.3. Others
13.2.3. Software
13.3. Market Attractiveness, by Product
13.4. Market Value Forecast, by Technology, 2017–2031
13.4.1. Multiplex RT-PCR
13.4.2. Flow Cytometry
13.4.3. Luminescence
13.4.4. Fluorescence
13.4.5. Others
13.5. Market Attractiveness, by Technology
13.6. Market Value Forecast, By Type, 2017–2031
13.6.1. Protein
13.6.1.1. Planar
13.6.1.2. Bead-based
13.6.2. Nucleic Acid
13.6.2.1. Planar
13.6.2.2. Bead-based
13.6.3. Cell
13.7. Market Attractiveness, By Type
13.8. Market Value Forecast, by Application, 2017–2031
13.8.1. Research & Development
13.8.1.1. Drug Discovery & Research
13.8.1.2. Biomarker Research & Application
13.8.2. Diagnosis
13.8.2.1. Infectious Diseases
13.8.2.2. Autoimmune Diseases
13.8.2.3. Cancer
13.8.2.4. Cardiovascular Diseases
13.8.2.5. Neuroendocrine Diseases
13.8.2.6. Others
13.8.3. Others
13.9. Market Attractiveness, by Application
13.10. Market Value Forecast, by End-user, 2017–2031
13.10.1. Biotechnology & Biopharmaceutical Companies
13.10.2. Academic & Research Centers
13.10.3. Diagnostic Centers
13.10.4. Hospitals
13.10.5. Others
13.11. Market Attractiveness, by End-user
13.12. Market Value Forecast, by Country/Sub-region, 2017–2031
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Market Attractiveness Analysis
13.13.1. By Product
13.13.2. By Technology
13.13.3. By Type
13.13.4. By Application
13.13.5. By End-user
13.13.6. By Country/Sub-region
14. Asia Pacific Multiplex Assays Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Product, 2017–2031
14.2.1. Instruments
14.2.2. Consumables
14.2.2.1. Reagents & Kits
14.2.2.2. Micropipettes & Microplates
14.2.2.3. Others
14.2.3. Software
14.3. Market Attractiveness, by Product
14.4. Market Value Forecast, by Technology, 2017–2031
14.4.1. Multiplex RT-PCR
14.4.2. Flow Cytometry
14.4.3. Luminescence
14.4.4. Fluorescence
14.4.5. Others
14.5. Market Attractiveness, by Technology
14.6. Market Value Forecast, By Type, 2017–2031
14.6.1. Protein
14.6.1.1. Planar
14.6.1.2. Bead-based
14.6.2. Nucleic Acid
14.6.2.1. Planar
14.6.2.2. Bead-based
14.6.3. Cell
14.7. Market Attractiveness, By Type
14.8. Market Value Forecast, by Application, 2017–2031
14.8.1. Research & Development
14.8.1.1. Drug Discovery & Research
14.8.1.2. Biomarker Research & Application
14.8.2. Diagnosis
14.8.2.1. Infectious Diseases
14.8.2.2. Autoimmune Diseases
14.8.2.3. Cancer
14.8.2.4. Cardiovascular Diseases
14.8.2.5. Neuroendocrine Diseases
14.8.2.6. Others
14.8.3. Others
14.9. Market Attractiveness, by Application
14.10. Market Value Forecast, by End-user, 2017–2031
14.10.1. Biotechnology & Biopharmaceutical Companies
14.10.2. Academic & Research Centers
14.10.3. Diagnostic Centers
14.10.4. Hospitals
14.10.5. Others
14.11. Market Attractiveness, by End-user
14.12. Market Value Forecast, by Country/Sub-region, 2017–2031
14.12.1. China
14.12.2. Japan
14.12.3. India
14.12.4. Australia & New Zealand
14.12.5. Rest of Asia Pacific
14.13. Market Attractiveness Analysis
14.13.1. By Product
14.13.2. By Technology
14.13.3. By Type
14.13.4. By Application
14.13.5. By End-user
14.13.6. By Country/Sub-region
15. Latin America Multiplex Assays Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Product, 2017–2031
15.2.1. Instruments
15.2.2. Consumables
15.2.2.1. Reagents & Kits
15.2.2.2. Micropipettes & Microplates
15.2.2.3. Others
15.2.3. Software
15.3. Market Attractiveness, by Product
15.4. Market Value Forecast, by Technology, 2017–2031
15.4.1. Multiplex RT-PCR
15.4.2. Flow Cytometry
15.4.3. Luminescence
15.4.4. Fluorescence
15.4.5. Others
15.5. Market Attractiveness, by Technology
15.6. Market Value Forecast, By Type, 2017–2031
15.6.1. Protein
15.6.1.1. Planar
15.6.1.2. Bead-based
15.6.2. Nucleic Acid
15.6.2.1. Planar
15.6.2.2. Bead-based
15.6.3. Cell
15.7. Market Attractiveness, By Type
15.8. Market Value Forecast, by Application, 2017–2031
15.8.1. Research & Development
15.8.1.1. Drug Discovery & Research
15.8.1.2. Biomarker Research & Application
15.8.2. Diagnosis
15.8.2.1. Infectious Diseases
15.8.2.2. Autoimmune Diseases
15.8.2.3. Cancer
15.8.2.4. Cardiovascular Diseases
15.8.2.5. Neuroendocrine Diseases
15.8.2.6. Others
15.8.3. Others
15.9. Market Attractiveness, by Application
15.10. Market Value Forecast, by End-user, 2017–2031
15.10.1. Biotechnology & Biopharmaceutical Companies
15.10.2. Academic & Research Centers
15.10.3. Diagnostic Centers
15.10.4. Hospitals
15.10.5. Others
15.11. Market Attractiveness, by End-user
15.12. Market Value Forecast, by Country/Sub-region, 2017–2031
15.12.1. Brazil
15.12.2. Mexico
15.12.3. Rest of Latin America
15.13. Market Attractiveness Analysis
15.13.1. By Product
15.13.2. By Technology
15.13.3. By Type
15.13.4. By Application
15.13.5. By End-user
15.13.6. By Country/Sub-region
16. Middle East & Africa Multiplex Assays Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Product, 2017–2031
16.2.1. Instruments
16.2.2. Consumables
16.2.2.1. Reagents & Kits
16.2.2.2. Micropipettes & Microplates
16.2.2.3. Others
16.2.3. Software
16.3. Market Attractiveness, by Product
16.4. Market Value Forecast, by Technology, 2017–2031
16.4.1. Multiplex RT-PCR
16.4.2. Flow Cytometry
16.4.3. Luminescence
16.4.4. Fluorescence
16.4.5. Others
16.5. Market Attractiveness, by Technology
16.6. Market Value Forecast, By Type, 2017–2031
16.6.1. Protein
16.6.1.1. Planar
16.6.1.2. Bead-based
16.6.2. Nucleic Acid
16.6.2.1. Planar
16.6.2.2. Bead-based
16.6.3. Cell
16.7. Market Attractiveness, By Type
16.8. Market Value Forecast, by Application, 2017–2031
16.8.1. Research & Development
16.8.1.1. Drug Discovery & Research
16.8.1.2. Biomarker Research & Application
16.8.2. Diagnosis
16.8.2.1. Infectious Diseases
16.8.2.2. Autoimmune Diseases
16.8.2.3. Cancer
16.8.2.4. Cardiovascular Diseases
16.8.2.5. Neuroendocrine Diseases
16.8.2.6. Others
16.8.3. Others
16.9. Market Attractiveness, by Application
16.10. Market Value Forecast, by End-user, 2017–2031
16.10.1. Biotechnology & Biopharmaceutical Companies
16.10.2. Academic & Research Centers
16.10.3. Diagnostic Centers
16.10.4. Hospitals
16.10.5. Others
16.11. Market Attractiveness, by End-user
16.12. Market Value Forecast, by Country/Sub-region, 2017–2031
16.12.1. GCC Countries
16.12.2. South Africa
16.12.3. Rest of Middle East & Africa
16.13. Market Attractiveness Analysis
16.13.1. By Product
16.13.2. By Technology
16.13.3. By Type
16.13.4. By Application
16.13.5. By End-user
16.13.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player – Competition Matrix (By Tier and Size of Companies)
17.2. Market Share Analysis, by Company (2022)
17.3. Company Profiles
17.3.1. DiaSorin S.p.A.
17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.1.2. Product Portfolio
17.3.1.3. Financial Overview
17.3.1.4. SWOT Analysis
17.3.1.5. Strategic Overview
17.3.2. Thermo Fisher Scientific, Inc.
17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.2.2. Product Portfolio
17.3.2.3. Financial Overview
17.3.2.4. SWOT Analysis
17.3.2.5. Strategic Overview
17.3.3. Seegene, Inc.
17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.3.2. Product Portfolio
17.3.3.3. Financial Overview
17.3.3.4. SWOT Analysis
17.3.3.5. Strategic Overview
17.3.4. Meso Scale Diagnostics, LLC
17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.4.2. Product Portfolio
17.3.4.3. Financial Overview
17.3.4.4. SWOT Analysis
17.3.4.5. Strategic Overview
17.3.5. Abcam Limited
17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.5.2. Product Portfolio
17.3.5.3. Financial Overview
17.3.5.4. SWOT Analysis
17.3.5.5. Strategic Overview
17.3.6. QIAGEN
17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.6.2. Product Portfolio
17.3.6.3. Financial Overview
17.3.6.4. SWOT Analysis
17.3.6.5. Strategic Overview
17.3.7. Bio-Rad Laboratories, Inc.
17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.7.2. Product Portfolio
17.3.7.3. Financial Overview
17.3.7.4. SWOT Analysis
17.3.7.5. Strategic Overview
17.3.8. Merck KGaA
17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.8.2. Product Portfolio
17.3.8.3. Financial Overview
17.3.8.4. SWOT Analysis
17.3.8.5. Strategic Overview
17.3.9. Quansys Biosciences
17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.9.2. Product Portfolio
17.3.9.3. Financial Overview
17.3.9.4. SWOT Analysis
17.3.9.5. Strategic Overview
17.3.10. Illumina, Inc.
17.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.3.10.2. Product Portfolio
17.3.10.3. Financial Overview
17.3.10.4. SWOT Analysis
17.3.10.5. Strategic Overview
List of Tables
Table 01: Global Multiplex Assays Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 02: Global Multiplex Assays Market Size (US$ Mn) Forecast, by Technology, 2017–2031
Table 03: Global Multiplex Assays Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 04: Global Multiplex Assays Market Size (US$ Mn) Forecast, By Type, 2017–2031
Table 05: Global Multiplex Assays Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 06: Global Multiplex Assays Market Size (US$ Mn) Forecast, by Region, 2017–2031
Table 07: North America Multiplex Assays Market Size (US$ Mn) Forecast, by Country, 2017–2031
Table 08: North America Multiplex Assays Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 09: North America Multiplex Assays Market Size (US$ Mn) Forecast, by Technology, 2017–2031
Table 10: North America Multiplex Assays Market Size (US$ Mn) Forecast, By Type, 2017–2031
Table 11: North America Multiplex Assays Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 12: North America Multiplex Assays Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 13: Europe Multiplex Assays Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Europe Multiplex Assays Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 15: Europe Multiplex Assays Market Size (US$ Mn) Forecast, by Technology, 2017–2031
Table 16: Europe Multiplex Assays Market Size (US$ Mn) Forecast, By Type, 2017–2031
Table 17: Europe Multiplex Assays Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 18: Europe Multiplex Assays Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 19: Asia Pacific Multiplex Assays Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Asia Pacific Multiplex Assays Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 21: Asia Pacific Multiplex Assays Market Size (US$ Mn) Forecast, by Technology, 2017–2031
Table 22: Asia Pacific Multiplex Assays Market Size (US$ Mn) Forecast, By Type, 2017–2031
Table 23: Asia Pacific Multiplex Assays Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 24: Asia Pacific Multiplex Assays Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 25: Latin America Multiplex Assays Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Latin America Multiplex Assays Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 27: Latin America Multiplex Assays Market Size (US$ Mn) Forecast, by Technology, 2017–2031
Table 28: Latin America Multiplex Assays Market Size (US$ Mn) Forecast, By Type, 2017–2031
Table 29: Latin America Multiplex Assays Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 30: Latin America Multiplex Assays Market Size (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Middle East & Africa Multiplex Assays Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Middle East & Africa Multiplex Assays Market Size (US$ Mn) Forecast, by Product, 2017–2031
Table 33: Middle East & Africa Multiplex Assays Market Size (US$ Mn) Forecast, by Technology, 2017–2031
Table 34: Middle East & Africa Multiplex Assays Market Size (US$ Mn) Forecast, By Type, 2017–2031
Table 35: Middle East & Africa Multiplex Assays Market Size (US$ Mn) Forecast, by Application, 2017–2031
Table 36: Middle East & Africa Multiplex Assays Market Size (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Multiplex Assays Market Size (US$ Mn) and Distribution (%), by Region, 2022–2031
Figure 02: Global Multiplex Assays Market Revenue (US$ Mn), by Product, 2022
Figure 03: Global Multiplex Assays Market Value Share, by Product, 2022
Figure 04: Global Multiplex Assays Market Revenue (US$ Mn), by Technology, 2022
Figure 05: Global Multiplex Assays Market Value Share, by Technology, 2022
Figure 06: Global Multiplex Assays Market Revenue (US$ Mn), By Type, 2022
Figure 07: Global Multiplex Assays Market Value Share, By Type, 2022
Figure 08: Global Multiplex Assays Market Revenue (US$ Mn), by Application, 2022
Figure 09: Global Multiplex Assays Market Value Share, by Application, 2022
Figure 10: Global Multiplex Assays Market Revenue (US$ Mn), by End-user, 2022
Figure 11: Global Multiplex Assays Market Value Share, by End-user, 2022
Figure 12: Global Multiplex Assays Market Value Share, by Region, 2022
Figure 13: Global Multiplex Assays Market Value (US$ Mn) Forecast, 2017–2031
Figure 14: Global Multiplex Assays Market Value Share Analysis, by Product, 2022–2031
Figure 15: Global Multiplex Assays Market Attractiveness Analysis, by Product, 2023–2031
Figure 16: Global Multiplex Assays Market Value Share Analysis, by Technology, 2022–2031
Figure 17: Global Multiplex Assays Market Attractiveness Analysis, by Technology, 2023–2031
Figure 18: Global Multiplex Assays Market Value Share Analysis, By Type, 2022–2031
Figure 19: Global Multiplex Assays Market Attractiveness Analysis, By Type, 2023–2031
Figure 20: Global Multiplex Assays Market Revenue (US$ Mn), by Application, 2022
Figure 21: Global Multiplex Assays Market Value Share, by Application, 2022
Figure 22: Global Multiplex Assays Market Revenue (US$ Mn), by End-user, 2022
Figure 23: Global Multiplex Assays Market Value Share, by End-user, 2022
Figure 24: Global Multiplex Assays Market Value Share Analysis, by Region, 2022–2031
Figure 25: Global Multiplex Assays Market Attractiveness Analysis, by Region, 2023–2031
Figure 26: North America Multiplex Assays Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 27: North America Multiplex Assays Market Attractiveness Analysis, by Country, 2023–2031
Figure 28: North America Multiplex Assays Market Value Share Analysis, by Country, 2022–2031
Figure 29: North America Multiplex Assays Market Value Share Analysis, by Product, 2022–2031
Figure 30: North America Multiplex Assays Market Value Share Analysis, by Technology, 2022–2031
Figure 31: North America Multiplex Assays Market Value Share Analysis, By Type, 2022–2031
Figure 32: North America Multiplex Assays Market Value Share Analysis, by Application, 2022–2031
Figure 33: North America Multiplex Assays Market Value Share Analysis, by End-user, 2022–2031
Figure 34: North America Multiplex Assays Market Attractiveness Analysis, by Product, 2023–2031
Figure 35: North America Multiplex Assays Market Attractiveness Analysis, by Technology, 2023–2031
Figure 36: North America Multiplex Assays Market Attractiveness Analysis, By Type, 2023–2031
Figure 37: North America Multiplex Assays Market Attractiveness Analysis, by Application, 2023–2031
Figure 38: North America Multiplex Assays Market Attractiveness Analysis, by End-user, 2023–2031
Figure 39: Europe Multiplex Assays Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 40: Europe Multiplex Assays Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 41: Europe Multiplex Assays Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 42: Europe Multiplex Assays Market Value Share Analysis, by Product, 2022–2031
Figure 43: Europe Multiplex Assays Market Value Share Analysis, by Technology, 2022–2031
Figure 44: Europe Multiplex Assays Market Value Share Analysis, By Type, 2022–2031
Figure 45: Europe Multiplex Assays Market Value Share Analysis, by Application, 2022–2031
Figure 46: Europe Multiplex Assays Market Value Share Analysis, by End-user, 2022–2031
Figure 47: Europe Multiplex Assays Market Attractiveness Analysis, by Product, 2023–2031
Figure 48: Europe Multiplex Assays Market Attractiveness Analysis, by Technology, 2023–2031
Figure 49: Europe Multiplex Assays Market Attractiveness Analysis, By Type, 2023–2031
Figure 50: Europe Multiplex Assays Market Attractiveness Analysis, by Application, 2023–2031
Figure 51: Europe Multiplex Assays Market Attractiveness Analysis, by End-user, 2023–2031
Figure 52: Asia Pacific Multiplex Assays Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 53: Asia Pacific Multiplex Assays Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 54: Asia Pacific Multiplex Assays Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 55: Asia Pacific Multiplex Assays Market Value Share Analysis, by Product, 2022–2031
Figure 56: Asia Pacific Multiplex Assays Market Value Share Analysis, by Technology, 2022–2031
Figure 57: Asia Pacific Multiplex Assays Market Value Share Analysis, By Type, 2022–2031
Figure 58: Asia Pacific Multiplex Assays Market Value Share Analysis, by Application, 2022–2031
Figure 59: Asia Pacific Multiplex Assays Market Value Share Analysis, by End-user, 2022–2031
Figure 60: Asia Pacific Multiplex Assays Market Attractiveness Analysis, by Product, 2023–2031
Figure 61: Asia Pacific Multiplex Assays Market Attractiveness Analysis, by Technology, 2023–2031
Figure 62: Asia Pacific Multiplex Assays Market Attractiveness Analysis, By Type, 2023–2031
Figure 63: Asia Pacific Multiplex Assays Market Attractiveness Analysis, by Application, 2023–2031
Figure 64: Asia Pacific Multiplex Assays Market Attractiveness Analysis, by End-user, 2023–2031
Figure 65: Latin America Multiplex Assays Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 66: Latin America Multiplex Assays Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 67: Latin America Multiplex Assays Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 68: Latin America Multiplex Assays Market Value Share Analysis, by Product, 2022–2031
Figure 69: Latin America Multiplex Assays Market Value Share Analysis, by Technology, 2022–2031
Figure 70: Latin America Multiplex Assays Market Value Share Analysis, By Type, 2022–2031
Figure 71: Latin America Multiplex Assays Market Value Share Analysis, by Application, 2022–2031
Figure 72: Latin America Multiplex Assays Market Value Share Analysis, by End-user, 2022–2031
Figure 73: Latin America Multiplex Assays Market Attractiveness Analysis, by Product, 2023–2031
Figure 74: Latin America Multiplex Assays Market Attractiveness Analysis, by Technology, 2023–2031
Figure 75: Latin America Multiplex Assays Market Attractiveness Analysis, By Type, 2023–2031
Figure 76: Latin America Multiplex Assays Market Attractiveness Analysis, by Application, 2023–2031
Figure 77: Latin America Multiplex Assays Market Attractiveness Analysis, by End-user, 2023–2031
Figure 78: Middle East & Africa Multiplex Assays Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2031
Figure 79: Middle East & Africa Multiplex Assays Market Attractiveness Analysis, by Country/Sub-region, 2023–2031
Figure 80: Middle East & Africa Multiplex Assays Market Value Share Analysis, by Country/Sub-region, 2022–2031
Figure 81: Middle East & Africa Multiplex Assays Market Value Share Analysis, by Product, 2022–2031
Figure 82: Middle East & Africa Multiplex Assays Market Value Share Analysis, by Technology, 2022–2031
Figure 83: Middle East & Africa Multiplex Assays Market Value Share Analysis, By Type, 2022–2031
Figure 84: Middle East & Africa Multiplex Assays Market Value Share Analysis, by Application, 2022–2031
Figure 85: Middle East & Africa Multiplex Assays Market Value Share Analysis, by End-user, 2022–2031
Figure 86: Middle East & Africa Multiplex Assays Market Attractiveness Analysis, by Product, 2023–2031
Figure 87: Middle East & Africa Multiplex Assays Market Attractiveness Analysis, by Technology, 2023–2031
Figure 88: Middle East & Africa Multiplex Assays Market Attractiveness Analysis, By Type, 2023–2031
Figure 89: Middle East & Africa Multiplex Assays Market Attractiveness Analysis, by Application, 2023–2031
Figure 90: Middle East & Africa Multiplex Assays Market Attractiveness Analysis, by End-user, 2023–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Multiplex Assays Market
*86 figures and 60 tables includes